Table 1. Participant and treatment characteristics.
| OVERALL | mEHT | Control | P Value | ||
|---|---|---|---|---|---|
| n | 206 | 104 [50.5%] | 102 [49.5%] | ||
| HIV Status | Positive | 105 [51%] | 51 [49%] | 54 [53%] | p = 575 |
| Negative | 101 [49%] | 53 [51%] | 48 [47%] | ||
| FIGO Staging | IIB | 75 [36%] | 40 [38%] | 35 [34%] | p = 0.825 |
| IIIA | 2 [1%] | 1 [1%] | 1 [1%] | ||
| IIIB | 129 [63%] | 63 [61%] | 66 [65%] | ||
| ECOG | 0 | 10 [5%] | 3 [3%] | 7 [7%] | p = 0.184 |
| 1 | 196 [95%] | 101 [97%] | 95 [93%] | ||
| Race | African | 191 [93%] | 96 [92%] | 95 [93%] | p = 0.035 |
| Caucasian | 5 [2%] | 4 [4%] | 1 [1%] | ||
| Other | 10 [5%] | 4 [4%] | 6 [6%] | ||
| Age [years] | Mean | 48.6 | 48.0 | 49.2 | p = 0.388 |
| SD | 10.49 | 10.77 | 10.22 | ||
| Range | 26–72 | 26–68 | 28–72 | ||
| BMI | Mean | 27.45 | 27.81 | 27.08 | p = 0.431 |
| SD | 6.68 | 6.95 | 6.41 | ||
| Range | 15–49 | 15–49 | 15–41.7 | ||
| Hb [g/dL] | Mean | 10.95 | 10.96 | 10.94 | P = 0.924 |
| SD | 2.26 | 2.13 | 2.39 | ||
| Range | 5.2–16.2 | 5.7–16.2 | 5.2–15.2 | ||
| CD4 count [cells/μL] in HIV positive | Mean | 550 | 576.5 | 524.9 | P = 0.315 |
| SD | 261.76 | 251.57 | 270.97 | ||
| Range | 95–1524 | 148–1204 | 95–1524 |
Abbreviations: mEHT: Modulated electro-hyperthermia; HIV: Human Immunodeficiency Virus; FIGO: International Federation of Gynaecology and Obstetrics; ECOG: Eastern Cooperative Oncology Group; SD: Standard Deviation; BMI: Body Mass Index; Hb: Haemoglobin.